Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs

Allergan and CRISPR specialist Editas have reinforced their gene editing R&D pact launched in March 2017.

SC1808_Genome Editing_1146082469_1200.jpg
Duo to jointly develop and market EDIT-101 For LCA10 • Source: Shutterstock

Progressing its R&D pact inked with Editas Medicine Inc. in March 2017, Allergan PLC on Aug. 7 confirmed it would take up the option of developing and marketing a candidate from the US-based CRISPR specialist to treat a retinal degenerative disorder, Leber congenital amaurosis (LCA).

The Irish-headquartered pharma said it would co-develop and co-commercialize EDIT-101 globally specifically for the treatment of LCA10. Also, Editas for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip